Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 703213, 9 pages
http://dx.doi.org/10.1155/2015/703213
Research Article

One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1

1Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Via S. Pansini 5, 80131 Napoli, Italy
2CEINGE Biotecnologie Avanzate S.C. a R.L., Via G. Salvatore 486, 80145 Napoli, Italy
3Associazione Culturale DiSciMuS RFC, 80026 Casoria, Italy

Received 4 August 2015; Accepted 5 October 2015

Academic Editor: Jorge G. Farías

Copyright © 2015 Emanuele Sasso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. T. Catanese, R. Graziani, T. von Hahn et al., “High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein,” Journal of Virology, vol. 81, no. 15, pp. 8063–8071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. C. De Lorenzo, D. B. Palmer, R. Piccoli, M. A. Ritter, and G. A. D'Alessio, “A new human antitumor immunoreagent specific for ErbB2,” Clinical Cancer Research, vol. 8, no. 6, pp. 1710–1719, 2002. View at Google Scholar · View at Scopus
  3. E. Scarselli, H. Ansuini, R. Cerino et al., “The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus,” The EMBO Journal, vol. 21, no. 19, pp. 5017–5025, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Bartosch, A. Vitelli, C. Granier et al., “Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor,” The Journal of Biological Chemistry, vol. 278, no. 43, pp. 41624–41630, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Evans, T. von Hahn, D. M. Tscherne et al., “Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry,” Nature Letters, vol. 446, pp. 801–805, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Ploss, M. J. Evans, V. A. Gaysinskaya et al., “Human occludin is a hepatitis C virus entry factor required for infection of mouse cells,” Nature, vol. 457, no. 7231, pp. 882–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Meuleman, M. T. Catanese, L. Verhoye et al., “A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo,” Hepatology, vol. 55, no. 2, pp. 364–372, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Yamashita, M. Iida, M. Tada et al., “Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus,” Journal of Pharmacology and Experimental Therapeutics, vol. 353, no. 1, pp. 112–118, 2015. View at Publisher · View at Google Scholar
  9. I. Fofana, S. E. Krieger, F. Grunert et al., “Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes,” Gastroenterology, vol. 139, no. 3, pp. 953–964, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Fukasawa, S. Nagase, Y. Shirasago et al., “Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model,” Journal of Virology, vol. 89, no. 9, pp. 4866–4879, 2015. View at Publisher · View at Google Scholar
  11. L. Mailly, F. Xiao, J. Lupberger et al., “Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody,” Nature Biotechnology, vol. 33, no. 5, pp. 549–554, 2015. View at Publisher · View at Google Scholar
  12. C. Welsch, F. S. Domingues, S. Susser et al., “Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus,” Genome Biology, vol. 9, no. 1, article R16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-M. Pawlotsky, “Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus,” Hepatology, vol. 53, no. 5, pp. 1742–1751, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. N. M. Dabbouseh and D. M. Jensen, “Future therapies for chronic hepatitis C,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 5, pp. 268–276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. T. J. Liang and M. G. Ghany, “Current and future therapies for hepatitis C virus infection,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1907–1917, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. T. Chung and T. F. Baumert, “Curing chronic hepatitis C—the arc of a medical triumph,” The New England Journal of Medicine, vol. 370, no. 17, pp. 1576–1578, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. S. Brown Jr., “Hepatitis C and liver transplantation,” Nature, vol. 436, no. 7053, pp. 973–978, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. U. Ravn, F. Gueneau, L. Baerlocher et al., “By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection,” Nucleic Acids Research, vol. 38, no. 21, article e193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Zhang, A. Torkamani, T. M. Jones, D. I. Ruiz, J. Pons, and R. A. Lerner, “Phenotype-information-phenotype cycle for deconvolution of combinatorial antibody libraries selected against complex systems,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 33, pp. 13456–13461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. D'Angelo, S. Kumar, L. Naranjo, F. Ferrara, C. Kiss, and A. R. Bradbury, “From deep sequencing to actual clones,” Protein Engineering Design and Selection, vol. 27, no. 10, pp. 301–307, 2014. View at Google Scholar
  21. A. Spiliotopoulos, J. Owen, B. Maddison, I. Dreveny, H. Rees, and K. Gough, “Sensitive recovery of recombinant antibody clones after their in silico identification within NGS datasets,” Journal of Immunological Methods, vol. 420, pp. 50–55, 2015. View at Publisher · View at Google Scholar
  22. R. Paciello, R. A. Urbanowicz, G. Riccio et al., “Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb,” Journal of General Virology, 2015. View at Publisher · View at Google Scholar